Sectors
BBIO
BridgeBio Pharma, Inc.
76.59
2 x 69.85
1 x 76.04
bid
ask
-
0.01
0.01%
2 @ 07:30 PM
76.59 +0.00 (0.00%)
| Ytd | 0.13% | |
| 1y | 47.97% |
75.03
day range
77.23
48.78
52 week range
93.42
| Open | 76.20 | Prev Close | 76.60 | Low | 75.03 | High | 77.23 | Mkt Cap | 14.97B |
| Vol | 2.06M | Avg Vol | 3.21M | EPS | -3.56 | P/E | N/A | Forward P/E | 500.00 |
| Beta | 0.98 | Short Ratio | 10.88 | Inst. Own | 99.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-28 | 50-d Avg | 79.86 | 200-d Avg | 73.60 | 1yr Est | 108.43 |
| Income Statement | |||
| Total Revenue | 243.68M | ||
| Revenues (USD) | 243.68M | ||
| Cost of Revenue | 15.05M | ||
| Gross Profit | 228.63M | ||
| Operating Expenses | 335.71M | ||
| Research and Development Expense | 149.45M | ||
| Selling, General and Administrative Expense | 186.26M | ||
| Operating Income | -107.08M | ||
| Interest Expense | 13.28M | ||
| Net Income | -152.22M | ||
| Net Income Common Stock | -152.22M | ||
| Net Income Common Stock (USD) | -152.22M | ||
| Consolidated Income | -155.89M | ||
| Net Income to Non-Controlling Interests | -3.67M | ||
| Earnings per Basic Share | -0.78 | ||
| Earnings per Basic Share (USD) | -0.78 | ||
| Earnings per Diluted Share | -0.78 | ||
| Earning Before Interest & Taxes (EBIT) | -138.94M | ||
| Earning Before Interest & Taxes (USD) | -138.94M | ||
| Weighted Average Shares | 195.79M | ||
| Weighted Average Shares Diluted | 195.79M | ||
| Balance Sheet | |||
| Cash and Equivalents | 677.91M | ||
| Cash and Equivalents (USD) | 677.91M | ||
| Investments | 97.34M | ||
| Investments Current | 42.25M | ||
| Investments Non-Current | 55.10M | ||
| Trade and Non-Trade Receivables | 254.48M | ||
| Current Assets | 1.09B | ||
| Property, Plant & Equipment Net | 22.31M | ||
| Total Assets | 1.22B | ||
| Debt Current | 551.27M | ||
| Total Debt | 2.49B | ||
| Current Liabilities | 890.65M | ||
| Debt Non-Current | 1.94B | ||
| Total Liabilities | 3.72B | ||
| Accumulated Retained Earnings (Deficit) | -4.14B | ||
| Accumulated Other Comprehensive Income | -7.00K | ||
| Shareholders Equity | -2.52B | ||
| Shareholders Equity (USD) | -2.52B | ||
| Assets Non-Current | 124.16M | ||
| Total Debt (USD) | 2.49B | ||
| Deferred Revenue | 15.97M | ||
| Goodwill and Intangible Assets | 26.64M | ||
| Inventory | 52.84M | ||
| Liabilities Non-Current | 2.83B | ||
| Trade and Non-Trade Payables | 27.20M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.68M | ||
| Net Cash Flow from Financing | -148.77M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -201.98M | ||
| Capital Expenditure | -443.00K | ||
| Issuance (Purchase) of Equity Shares | -131.77M | ||
| Issuance (Repayment) of Debt Securities | -431.00K | ||
| Net Cash Flow from Investing | 17.89M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 18.33M | ||
| Net Cash Flow from Operations | -71.10M | ||
| Share Based Compensation | 44.07M | ||